Compare AbbVie Inc (ABBV) vs Autozone Inc (AZO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Autozone Inc — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Autozone Inc trades at $3,060.03 (market cap $50.20B). The key difference: AbbVie Inc is far larger — about 9× Autozone Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Autozone Inc pays none. Which is the better fit depends on your goals.
| ABBV | AZO | |
|---|---|---|
Market Cap | $449.91B | $50.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $4.35K |
52-Week Low | $184.85 | $2.94K |
Enterprise Value | $513.38B | $62.58B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
AutoZone (AZO) trades at $3,074.86, down 2.67% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though profit margins have declined from 14.94% in 2022 to 13.19% in 2025. Recent Q1 2026 earnings beat expectations at $38.07 EPS versus $36.22 expected, while the board authorized an additional $1.5B stock repurchase in June 2026.
AZO presents a mixed outlook with 72.7% analyst buy ratings and $3,740 consensus target suggesting 21.6% upside, but faces technical headwinds and margin compression risks. Investment appeal hinges on international expansion execution and commercial segment growth offsetting domestic softness noted in recent earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →
